HARBIN, China, May 23, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that the Company recently attended the 111th China Import and Export Fair (the "Canton Fair") held in Guangzhou, China.
China Botanic showcased the Company's Siberian Ginseng (Acanthopanax) series products and its biopharmaceutical products, including Badger Oil and Ginseng and Venison Extract at the Canton Fair and received several orders with a total value of approximately RMB 6 million (or approximately $1.0 million).
Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic commented, "The Canton Fair is a great opportunity to showcase our products to several international participants and potential customers. Our products were well received at the Canton Fair and we are pleased to receive new orders of $1.0 million. We will continue to seek opportunities to attend similar public and industry events which provide us a platform to promote our products and capabilities and build strong industry relationships."
About China Import and Export FairChina Import and Export Fair (also called the Canton Fair) was inaugurated in spring 1957. It is co-hosted biannually by the Ministry of Commerce of PRC and the People's Government of Guangdong Province in Guangzhou, every spring and autumn. The Fair ranks the top in the world in terms of the scale for a single exhibition, and it is a comprehensive international trading event with the longest history, the largest scale, the most complete exhibit variety, and the biggest buyer attendance. Held from April 15, 2012 to May 5, 2012, the 111th Canton Fair attracted over 63,000 business attendees and created over $3.6 billion export volume. For more information, please visit http://www.cantonfair.org.cn/en/index.asp.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:CCG Investor Relations:China Botanic Pharmaceutical Inc.
Mr. Mark Collinson, PartnerMs. Portia Tan, IR Contact
Phone: +1-310-954-1343 (Los Angeles)Tel: 86-451-8260-2162
|SOURCE China Botanic Pharmaceutical Inc.|
Copyright©2010 PR Newswire.
All rights reserved